Answers are grounded in this paper and cite their sources.
Switching between calcitonin gene-related peptide (CGRP) and monoclonal antibodies (mAbs) may be a beneficial strategy after discontinuation. The aim of this study was to evaluate switching outcomes of effectiveness/tolerability. Retrospective multicentric study of migraine patients who switched to another CGRP–mAb due to lack of tolerability or effectiveness (defined as < 30% reduction of monthly headache days [MHD]). Assessment was performed before and 3 months after switch. The main outcome was the response rate of MHD. Secondary outcomes included other effectiveness/tolerability measures. 90patients were included: 75(83.3%) women, 72(80%) chronic, and 18(20%) episodic migraine. Mean age was 45.9 ± 11 years and mean duration of migraine was 29.2 ± 12.4 years. Mean time under first mAb prior to switch was 10.4 ± 4.9 months. Most frequent switches were erenumab-galcanezumab 38 (42.2%) and erenumab–fremanezumab 21 (23.3%). Lack of effectiveness (50/90, 55.6%) or tolerability (40/90, 44.4%) provoked switching. Most common adverse events (AEs) leading to discontinuation were constipation and flu-like syndrome in 16 (40%) patients each. Response rate (RR) of MHD 30%–50% occurred in 10 patients (11.1%), ≥ 50% in 32 (35.6%) and < 30% in 48 (53.3%) patients. Significant reduction was proved after switch in MHD (20 [IQR:15–29] vs 13 [IQR:7–23]; p < .001) and monthly migraine days (15 [IQR:12–20] vs 10 [IQR:7–16]; p < .001). After switching, 38 (42.2%) experienced AEs, but tolerability improved in 50% of patients who discontinued due to lack of tolerability. RR compared between switches to different CGRP-mAb classes showed no differences. Switching may become an individualized strategy in migraine refractory patients who discontinue CGRP–mAbs due to lack of effectiveness/tolerability. In this study, supportive data are provided to the growing evidence of switch and future needs are highlighted. El switch entre anticuerpos monoclonales (AMCs) frente al CGRP podría suponer una estrategia eficaz tras la discontinuación. El objetivo fue evaluar los resultados de efectividad/tolerabilidad del switch. Estudio retrospectivo multicéntrico incluyendo pacientes con migraña que realizaron switch a otro AMC-anti-CGRP debido a falta de tolerabilidad o efectividad (< 30% reducción días cefalea mensual[DCM]). Fueron evaluados previamente y tres meses tras switch. La variable principal fue la tasa de respuesta en DCM. Los objetivos secundarios incluyeron otras medidas de efectividad/tolerabilidad. Se incluyeron 90pacientes: 75(83.3%) mujeres, 72(80%) con migraña crónica y 18(20%) episódica. La edad media fue 45.9 ± 11años, la duración media de migraña 29.2 ± 12.4años. El tiempo medio con el primer AMC fue 10.4 ± 4.9meses. Los switch más frecuentes fueron erenumab-galcanezumab 38(42.2%) y erenumab-fremanezumab 21(23.3%). La falta de efectividad (50/90, 55.6%) o tolerabilidad (40/90, 44.4%) causaron el switch. Los efectos adversos(EAs) más frecuentes fueron estreñimiento y síndrome pseudogripal en 16(40%) respectivamente. La reducción de DCM fue 30–50% en 10 pacientes(11.1%), ≥ 50% en 32(35.6%) y < 30% en 48(53.3%). Se demostró una reducción significativa de DCM tras el switch (20[IQR:15–29] vs 13[IQR:7–23];p < 0,001) y DMM (15[IQR:12–20] vs 10[IQR:7–16];p < 0,001). Tras el switch, 38 pacientes(42.2%) experimentaron EAs, pero la tolerabilidad mejoró en 50% de pacientes que discontinuaron por ello. La reducción DCM comparada entre AMC con distinta diana(CGRP vs. ligando) no mostró diferencias. El switch podría suponer una estrategia terapéutica en pacientes refractarios tras discontinuación de AMC anti-CGRP por falta de efectividad/tolerabilidad. Este estudio aporta evidencia adicional del switch y plantea nuevas necesidades y futuras investigaciones.
No takes yet. Share an insight, caveat, or question.
Arzalluz-Luque et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: